"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 1 | 4 |
| 2004 | 8 | 2 | 10 |
| 2005 | 3 | 1 | 4 |
| 2006 | 4 | 1 | 5 |
| 2007 | 5 | 0 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 5 | 0 | 5 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct; 20(10):1161-6.
-
Adams CM, Eischen CM. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer. Cancer Res. 2014 Jul 15; 74(14):3923-34.
-
Gramling MW, Eischen CM. Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death Differ. 2012 Jul; 19(7):1220-7.
-
Porcu P. A look at the National Comprehensive Cancer Network guidelines for cutaneous lymphomas. Clin Lymphoma Myeloma Leuk. 2010 Sep; 10 Suppl 2:S109-11.
-
Lessin SR, Porcu P. The state of cutaneous lymphomas: a call to action. Clin Lymphoma Myeloma Leuk. 2010 Sep; 10 Suppl 2:S55-8.
-
Arrate MP, Vincent T, Odvody J, Kar R, Jones SN, Eischen CM. MicroRNA biogenesis is required for Myc-induced B-cell lymphoma development and survival. Cancer Res. 2010 Jul 15; 70(14):6083-92.
-
Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 3; 29(22):3287-96.
-
Sluss HK, Gannon H, Coles AH, Shen Q, Eischen CM, Jones SN. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis. Mol Cancer Res. 2010 Feb; 8(2):216-22.
-
Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010 Jan 20; 28(3):418-23.
-
Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene. 2010 Mar 4; 29(9):1260-9.